Transgene Biotek Share Price
Free Demat with Zero AMC*
+ Free 1st Year AMC
Summary
The stock has recorded a trading volume of 5,572 shares,. Its Average Traded Price (ATP) is ₹2.50, while the Last Traded Quantity at the Last Traded Price (LTQ@LTP) is 4 @ ₹2.49.
Transgene Biotek has an upper circuit limit of ₹2.94 and a lower circuit limit of ₹1.96. The total value traded stands at ₹13930.00, and the delivery percentage for the day is 60.81%.
The stock is currently traded with a market lot size of 1. Transgene Biotek also offers a dividend yield of 0%.
Transgene Biotek Share Price Chart
Transgene Biotek Share Key Metrics
Volume
5572.00
Market Cap
18.94 CR
LTQ@LTP
4@2.49
ATP
2.5
Var Margin
28.65 %
Circuit Range
1.96-2.94
Delivery %
60.81 %
Value
13930.00
ASM/GSM
No
Market Lot
1
Transgene Biotek Resistance and Support
Pivot 2.48
Resistance
First Resistance
2.56
Second Resistance
2.68
Third Resistance
2.76
Support
First Support
2.36
Second Support
2.28
Third Support
2.16
Transgene Biotek Shareholding Pattern
View More- 2016-17
- 2017-18
- 2018-19
- 2019-20
- 2020-21
- 2021-22
- 2022-23
- 2023-24
- 2024-25
- 2025-26
- 2026-27
Total Promoters
Transgene Biotek Corporate Actions
| Date | Agenda |
|---|---|
| 2026-11-13 | Quarterly Results |
| 2026-10-10 | Others |
| 2026-08-07 | Quarterly Results & Others |
| 2026-05-29 | Audited Results |
| 2026-02-13 | Quarterly Results |
| 2025-11-14 | Quarterly Results |
| 2025-08-07 | Quarterly Results |
| 2025-05-07 | Audited Results |
| 2025-01-24 | Quarterly Results |
| 2024-11-12 | Quarterly Results & A.G.M. |
| 2024-08-10 | Quarterly Results |
Transgene Biotek News
Transgene Biotek Ltd - 526139 - Intimation Of Book Closure And Cut -Off Date For The 36Th Annual General Meeting Of Transgene Biotek Limited
Transgene Biotek: 36th AGM scheduled for 30-Dec-2026. Book Closure from 24-Dec-2026 to 30-Dec-2026. E-Voting cut-off on 23-Dec-2026.
Nov 13 2026 17:07:34
Transgene Biotek Ltd - 526139 - Board Meeting Outcome for Outcome Of The Board Meeting Held On Friday, 13Th November, 2026.
Transgene Biotek announced its Q2 FY27 results, reporting a cons. revenue of ₹6 lakhs and a narrowed net loss of ₹34.53 lakhs. The board approved the re-appointment of Dr. K. Koteswara Rao as Chairman and Managing Director for one year.
Nov 13 2026 13:19:00
Transgene Biotek Ltd - 526139 - Board Meeting Intimation for Intimation Of The Board Meeting To Be Held On Friday, 13Th November, 2026.
Transgene Biotek board will meet on 13 Nov 2026 to consider financial results. The board will also consider the re-appointment of Dr K Koteswara Rao as Chairman & Managing Director.
Nov 07 2026 16:56:44
Transgene Biotek Ltd - 526139 - Board Meeting Outcome for Outcome Of The Board Meeting Held On 04Th November, 2026 Pursuant To Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.
Transgene Biotek announced the mid-term resignation of statutory auditor Harish Gummadi & Co, effective November 3, 2026, citing a medical emergency. The board has appointed Ranganath Prasad & Co to fill the casual vacancy.
Nov 04 2026 15:18:45
Transgene Biotek Ltd - 526139 - Board Meeting Outcome for Outcome Of The Board Meeting Held On 02Nd November, 2026 Pursuant To Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.
Transgene Biotek announced the resignation of its statutory auditor, Eswara Rao & Co., effective October 28, 2026, citing a medical emergency. The board has appointed Harish Gummadi & Co. to fill the casual vacancy.
Nov 02 2026 11:54:15
Transgene Biotek Ltd - 526139 - Announcement under Regulation 30 (LODR)-Resignation of Statutory Auditors
Transgene Biotek announced the mid-term resignation of its statutory auditor, Vasavi & Co., effective September 22, 2026. The auditor cited pre-occupation with other professional assignments and confirmed no other material reasons for the early exit.
Oct 31 2026 19:23:36
Transgene Biotek Ltd - 526139 - Announcement under Regulation 30 (LODR)-Resignation of Statutory Auditors
Transgene Biotek announced the mid-term resignation of its statutory auditor, Eswara Rao & Co., effective October 28, 2026. The firm cited a family medical emergency preventing them from completing the September quarter limited review, while confirming no instances of management non-cooperation.
Oct 31 2026 19:19:59
Transgene Biotek Ltd - 526139 - Announcement under Regulation 30 (LODR)-Resignation of Statutory Auditors
Transgene Biotek announced the mid-term resignation of statutory auditor Eswara Rao and Co. effective October 28, 2026. The firm resigned just 18 days after appointment, citing a partner medical emergency and insufficient time to complete the upcoming Q2 financial review.
Oct 31 2026 13:13:51
Transgene Biotek Ltd - 526139 - Announcement under Regulation 30 (LODR)-Resignation of Statutory Auditors
Transgene Biotek announced the mid-term resignation of statutory auditor Eswara Rao & Co., effective October 28, 2026. The firm resigned just 18 days after being appointed to fill a casual vacancy created by the previous auditor's exit, citing pre-occupation in other assignments.
Oct 29 2026 10:20:36
Transgene Biotek Management
| Name | Position |
|---|---|
| K Koteswara Rao | Chairman & Managing Director |
| Sujana Kadiam | Non Executive Independent Director |
Transgene Biotek Similar Stocks
Transgene Biotek FAQs
Open Your Free
Demat Account Now!
AMC for First Year
Auto Square Off Charges
+ Free 1st Year AMC
13 Lakh+ Clients
Expert-Backed
Premium Tools

Open Your Free
Demat Account Now!
AMC For First Year
Account Opening Fee
+ Free 1st Year AMC
13 Lakh+ Clients
Expert-Backed
Premium Tools
Invest in TRABI
Account Opening Fee AMC for 1st Year Auto Square Off Charges Call & Trade
+ Free 1st Year AMC